INDEGENE
Back to Balance Sheet
|
INDEGENE Last 5 Year Total Non-Current Liabilities History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Total Non-Current Liabilities | ₹435 Cr | ₹584 Cr | ₹80 Cr | ₹27 Cr | ₹331 Cr |
What is the latest Total Non-Current Liabilities ratio of INDEGENE ?
Year | Total Non-Current Liabilities |
---|---|
Mar2024 | ₹435 Cr |
Mar2023 | ₹584 Cr |
Mar2022 | ₹80 Cr |
Mar2021 | ₹27 Cr |
Mar2020 | ₹331 Cr |
How is Total Non-Current Liabilities of INDEGENE Trending?
Years | Total Non-Current Liabilities | % Change | |
---|---|---|---|
Mar2024 | ₹435 Cr | -25.54 | |
Mar2023 | ₹584 Cr | 630.10 | |
Mar2022 | ₹80 Cr | 198.58 | |
Mar2021 | ₹27 Cr | -91.90 | |
Mar2020 | ₹331 Cr | - |
Compare Total Non-Current Liabilities of peers of INDEGENE
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
INDEGENE | ₹13,870.8 Cr | 7.3% | 12.3% | NA | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹411,306.0 Cr | -2.5% | 7.6% | 4.7% | Stock Analytics | |
DIVIS LABORATORIES | ₹150,343.0 Cr | -3% | 3.4% | 61.5% | Stock Analytics | |
CIPLA | ₹117,323.0 Cr | -1.6% | 3% | -3.4% | Stock Analytics | |
TORRENT PHARMACEUTICALS | ₹108,619.0 Cr | -0.3% | 9% | 22.3% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹95,941.5 Cr | -1.2% | 2.9% | -6.4% | Stock Analytics |
INDEGENE Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
INDEGENE | 7.3% |
12.3% |
|
SENSEX | -1.8% |
2.7% |
5% |
You may also like the below Video Courses